General Information of Drug (ID: DM4G1SP)

Drug Name
AMG 596 Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma multiforme 2A00.0 Phase 1 [1]
Recurrent glioblastoma 2A00.00 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM4G1SP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [4]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [5]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [6]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [7]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [8]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [9]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [10]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [11]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [12]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anti-EGFRvIII CAR transduced PBL DMDKTYU Brain cancer 2A00 Phase 1/2 [14]
EGFRvIII CAR DMC284G Glioblastoma multiforme 2A00.0 Phase 1/2 [15]
Anti-EGFR V III CAR-T cells DM8EAGV Glioma 2A00.0 Phase 1/2 [16]
D2C7 DMIMK84 Glioblastoma of brain 2A00.00 Phase 1 [17]
EGFRvIII CAR T cells DM6XWV4 Glioblastoma multiforme 2A00.0 Phase 1 [18]
CAR-T cells targeting EGFRviii DMRSG04 Glioblastoma multiforme 2A00.0 Phase 1 [19]
Anti-EGFRvIII CAR T cells DM73920 Glioblastoma multiforme 2A00.0 Phase 1 [20]
CART-EGFRvIII T cells DMGPR1C Recurrent glioblastoma 2A00.00 Phase 1 [21]
EGFRvIII-CARs DMA46RN Recurrent glioblastoma 2A00.00 Phase 1 [22]
CAR-T cells targeting EGFRviii DMRSG04 Glioblastoma multiforme 2A00.0 Phase 1 [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor variant III (EGFR vIII) TTZ6B2I EGFR_HUMAN Inhibitor [3]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Inhibitor [3]

References

1 ClinicalTrials.gov (NCT03296696) Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Amgen.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
6 Clinical pipeline report, company report or official report of Genmab.
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
8 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
9 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
10 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
11 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
12 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
13 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
14 ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
15 EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
16 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
17 Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
18 ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
19 ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
20 ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
21 ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
22 ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
23 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.